These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 12465452)

  • 1. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis.
    Wright GL
    Expert Rev Mol Diagn; 2002 Nov; 2(6):549-63. PubMed ID: 12465452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid.
    Li J; Zhao J; Yu X; Lange J; Kuerer H; Krishnamurthy S; Schilling E; Khan SA; Sukumar S; Chan DW
    Clin Cancer Res; 2005 Dec; 11(23):8312-20. PubMed ID: 16322290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteome analysis for the identification of tumor-associated biomarkers in gastrointestinal cancer.
    Fels LM; Buschmann T; Meuer J; Reymond MA; Lamer S; Röcken C; Ebert MP
    Dig Dis; 2003; 21(4):292-8. PubMed ID: 14752218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays.
    Fung ET; Yip TT; Lomas L; Wang Z; Yip C; Meng XY; Lin S; Zhang F; Zhang Z; Chan DW; Weinberger SR
    Int J Cancer; 2005 Jul; 115(5):783-9. PubMed ID: 15704152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform.
    Shiwa M; Nishimura Y; Wakatabe R; Fukawa A; Arikuni H; Ota H; Kato Y; Yamori T
    Biochem Biophys Res Commun; 2003 Sep; 309(1):18-25. PubMed ID: 12943657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contributions of advanced proteomics technologies to cancer diagnosis.
    Ciordia S; de Los Ríos V; Albar JP
    Clin Transl Oncol; 2006 Aug; 8(8):566-80. PubMed ID: 16952845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.
    Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM
    J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Screening of differentially expressed proteins associated with directional highly lymphatic metastasis in ovarian carcinoma cell lines using SELDI-TOF-MS technology].
    Guan X; Li DR; Wang Q; Li L; Ruan HY; Zhang W
    Ai Zheng; 2008 Nov; 27(11):1155-60. PubMed ID: 19000445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer.
    Yang Y; Pospisil P; Iyer LK; Adelstein SJ; Kassis AI
    PLoS One; 2008; 3(11):e3661. PubMed ID: 18987750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification.
    Issaq HJ; Veenstra TD; Conrads TP; Felschow D
    Biochem Biophys Res Commun; 2002 Apr; 292(3):587-92. PubMed ID: 11922607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform.
    Schiffer E; Mischak H; Theodorescu D; Vlahou A
    World J Urol; 2008 Feb; 26(1):67-74. PubMed ID: 18175124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical proteomics for cancer biomarker discovery and therapeutic targeting.
    Krieg RC; Paweletz CP; Liotta LA; Petricoin EF
    Technol Cancer Res Treat; 2002 Aug; 1(4):263-72. PubMed ID: 12625785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic approaches to biomarker discovery in prostate and bladder cancers.
    Adam BL; Vlahou A; Semmes OJ; Wright GL
    Proteomics; 2001 Oct; 1(10):1264-70. PubMed ID: 11721637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers.
    Verma M; Wright GL; Hanash SM; Gopal-Srivastava R; Srivastava S
    Ann N Y Acad Sci; 2001 Sep; 945():103-15. PubMed ID: 11708463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma proteomic pattern as biomarkers for ovarian cancer.
    Lin YW; Lin CY; Lai HC; Chiou JY; Chang CC; Yu MH; Chu TY
    Int J Gynecol Cancer; 2006; 16 Suppl 1():139-46. PubMed ID: 16515582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue and serum proteomic profiling for diagnostic and prognostic bladder cancer biomarkers.
    Schwamborn K; Gaisa NT; Henkel C
    Expert Rev Proteomics; 2010 Dec; 7(6):897-906. PubMed ID: 21142890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of oncoproteomics to cancer biomarker discovery.
    Cho WC
    Mol Cancer; 2007 Apr; 6():25. PubMed ID: 17407558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass spectrometric characterization of protein structure details refines the proteome signature for invasive ductal breast carcinoma.
    Röwer C; Koy C; Hecker M; Reimer T; Gerber B; Thiesen HJ; Glocker MO
    J Am Soc Mass Spectrom; 2011 Mar; 22(3):440-56. PubMed ID: 21472563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery.
    Celis JE; Gromov P; Cabezón T; Moreira JM; Ambartsumian N; Sandelin K; Rank F; Gromova I
    Mol Cell Proteomics; 2004 Apr; 3(4):327-44. PubMed ID: 14754989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomics of breast carcinoma.
    Somiari RI; Somiari S; Russell S; Shriver CD
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Feb; 815(1-2):215-25. PubMed ID: 15652811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.